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PURPOSE. To assess the phenotypic variability and natural course of inherited retinal diseases
(IRDs) caused by EYS mutations.
METHODS. Multiethnic cohort study (N ¼ 30) with biallelic EYS variants from a clinical IRD
database (retinitis pigmentosa [RP], N ¼ 27; cone-rod dystrophy [CRD], N ¼ 1; and macular
dystrophy, N ¼ 2). In vitro minigene splice assay was performed to determine the effect on
EYS pre-mRNA splicing of the c.1299þ5_1299þ8del variant in macular dystrophy patients.
RESULTS. We found 27 different EYS variants in RP patients and 7 were novel. The rate of visual
field loss of the V4e isopter area was 0.84 6 0.44 ln(deg2) per year, and the rate of visual
acuity loss was 0.75 Early Treatment Diabetic Retinopathy Study letters per year. Ellipsoid
zone width was correlated with area of the hyperautofluorescent ring, with rs ¼ 0.78 and P <
0.001. Rate of decline in ellipsoid zone width was 57 6 17 lm per year (P < 0.01) (n ¼ 14)
or 3.69% 6 0.51% from baseline per year (P < 0.001). An isolated CRD patient carried a
homozygous EYS variant (c.9405T>A), previously identified in RP patients. Two siblings with
macular dystrophy carried compound heterozygous EYS variants: c.1299þ5_1299þ8del and
c.6050G>T. The former was novel and shown to result in skipping of exon 8, and the latter
was a known RP variant.
CONCLUSIONS. We report on EYS-associated macular dystrophy, extending the spectrum of EYS-
associated IRDs. We observed heterogeneity between RP patients in age of onset and disease
progression. Identical EYS variants were found in cases with RP, CRD, and macular dystrophy.
Screening for EYS variants in CRD and macular dystrophy patients might increase the
diagnostic yield in previously unsolved cases.
Keywords: retinitis pigmentosa, cone-rod dystrophy, macular dystrophy, inherited retinal
disease, EYS
Inherited retinal diseases (IRDs) are a heterogeneous group ofgenetic eye diseases characterized by progressive degenera-
tion of photoreceptor and/or retinal pigment epithelium (RPE)
cells, leading to severe visual impairment and blindness.
Retinitis pigmentosa (RP), a rod-cone dystrophy, is the most
common subtype of IRD with an estimated prevalence of 1 in
4000 individuals.1 Patients report night blindness and visual
field (VF) constriction from early adolescence and gradually
decreasing visual acuity later in life. Over 250 genes have been
described to be mutated in IRD, of which several can be
mutated in different clinical subtypes of IRD.2
Eyes shut homolog (EYS; OMIM: 612424) was first reported
in 2008 by two independent groups,3,4 and both described this
gene as the human ortholog of Drosophila ‘‘eyes shut’’ (eys),
also known as Spacemaker (spam). Mutations in EYS account
for ~5% to 35% of European and Asian autosomal recessive
retinitis pigmentosa cases5–11 but have also been described in
three patients with autosomal recessive cone-rod dystrophy
(CRD).4,12,13 EYS is located on chromosome 6p12 (RP25
locus), spans over 2 Mb, and consists of 44 exons that together
code for a protein that is predicted to harbor 27 epidermal
growth factor (EGF)-like domains and 5 laminin G-like domains.
There are at least four isoforms, all of which are expressed in
the human retina.14 The Drosophila ortholog plays an
important role in retinal morphogenesis and architecture.15 In
zebrafish, Eys is expressed in the outer segments and
connecting cilium/transition zone (CC/TZ) of both rod and
cone photoreceptors.16–18 Functional studies in zebrafish
suggest Eys helps to maintain the stability of the ciliary
axoneme in both rods and cones and the integrity of the
ciliary pocket in cones.16–18 Eys knockout zebrafish showed a
cone-rod pattern of retinal degeneration,16 and the Eys protein
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was assumed to be essential for the structural integrity of
photoreceptor cells.18 However, the exact function of the EYS
protein and the role of the different isoforms in the human
retina still remains unclear.
We have assessed the spectrum of retinal disease and the
course of visual function in our multiethnic cohort of 30
patients carrying biallelic EYS mutations to improve patient
counseling on prognosis and to provide guidance for the
timing of therapeutic intervention if available. Twenty-seven
patients were diagnosed with RP, one patient was diagnosed
with CRD, and two patients with macular dystrophy. To find
an explanation for the generalized versus more localized
retinal dystrophy among our subjects, we performed func-
tional testing of a novel splice site variant and bioinformati-
cally assessed the nature of other (presumed) pathogenic
variants.
MATERIALS AND METHODS
Study Subjects
We gathered all available DNA testing results from IRD patients
from two tertiary care hospitals (The Rotterdam Eye Hospital
and Erasmus Medical Center) and selected patients with
biallelic EYS mutations. In total, we included 30 IRD patients
from 25 families. Four patients were previously described by
Littink et al.5 Eighteen patients were isolated cases with a
negative family history of inherited retinal dystrophies. Twenty-
seven patients were diagnosed with RP, one patient with CRD,
and two patients with macular dystrophy based on clinical
characteristics, retinal imaging, and visual function testing. The
study protocol adhered to the tenets of the Declaration of
Helsinki and was approved by the Institutional Review Board
and the Ethics Committee of the Erasmus Medical Center
(Rotterdam, The Netherlands).
Molecular Diagnosis
The molecular diagnosis of EYS variants (NM_001142800.1)
was made using Sanger sequencing (9 patients), autosomal
recessive RP APEX genotyping array (3 patients), and targeted
analysis of 286 IRD-associated genes (Supplemental data) after
exome sequencing (18 patients). To determine the effect of the
c.1299þ5_1299þ8del variant on EYS pre-mRNA splicing, an in
vitro minigene splice assay was performed. For this, we
generated a wild-type minigene and a mutant minigene
harboring the c.1299þ5_1299þ8del variant, which each
contain exon 8 and parts of the flanking introns of EYS (Fig.
1A). To investigate if the c.1299þ5_1299þ8del variant leads to
alterations in splicing, HEK293T cells were transfected with
the wild type or mutant minigene constructs, followed by RT-
PCR analysis. A detailed description of the applied techniques
is provided in the Supplementary data.
Clinical Work-Up
Data were collected from our own medical charts, and historic
data were retrieved from referring ophthalmologists to
maximize the follow-up period. Ophthalmologic examination
included best-corrected visual acuity (BCVA), Goldmann
kinetic VF testing, full-field electroretinogram (ffERG) accord-
ing to International Society for Clinical Electrophysiology of
Vision standards (Diagnosys, Lowell, MA, USA), multifocal
electroretinogram (Diagnosys), dilated fundus examination,
color fundus photography (D300 [Nikon, Tokyo, Japan]; TRC-
NW65; Topcon, Tokyo, Japan; and Zeiss FF 450 Plus Fundus
Camera [Carl Zeiss Meditec, Jena, Germany]), spectral-domain
optical coherence tomography (SD-OCT) (Spectralis; Heidel-
berg Engineering GmbH, Dossenheim, Germany), and 308 field
fundus autofluorescence (FAF) (Spectralis). Quantative image
analysis was performed with Heidelberg Eye Explorer Soft-
ware. The area inside the hyperautofluorescent ring was
measured from the outer border by using a free-hand drawing
tool (Supplementary Fig. S1A). The width of the ellipsoid zone
was measured in the horizontal foveal B-scan with a distance
measurement tool (Supplementary Fig. S1B). VFs were
digitized using a method described by Dagnelie.19 We
measured the retinal area of the V4e target because this target
was consistently used in all examinations.
Statistical Analysis
Visual impairment was defined as either low vision (BCVA
worse than 0.50 logMAR but equal or better than 1.30 logMAR
and/or central VF radius of the V4e target smaller than 208 but
equal or larger than 108 in the better eye) or blindness (BCVA
worse than 1.30 logMAR and/or central VF radius of the V4e
target smaller than 108 in the better eye) in accordance with
the World Health Organization criteria. We used the Spearman
correlation coefficient to analyze the strength and the direction
of the association between variables. For analysis of the VF
area, the ellipsoid zone width, and the area of the hyper-
autofluorescent ring on FAF, we used the mean of the right and
the left eye as they were significantly correlated (ellipsoid zone
rs¼0.95, P < 0.001; and hyperautofluorescent ring rs¼0.96, P
 0.001). To calculate the annual rate of decline in visual
function, we used mixed effects linear regression modeling
with visual acuity in logMAR and with log-transformed area of
the V4e isopter expressed in degrees squared (deg2) for VF and
corrected for repeated measurements by entering a fixed
effect.20 Patients with a single visit were excluded from
longitudinal analysis. We used a Student’s t-test to compare
differences in age of onset, age at diagnosis, and age at last
examination between patients with and without constricted
VFs at last examination. To calculate the annual rate of decline
in ellipsoid zone width, we used mixed effects linear
regression modeling and corrected for repeated measurements
by entering a fixed effect. Additionally, we calculated the rate
of decline of the ellipsoid zone width as a percentage of
baseline allowing comparison with other studies.21,22
RESULTS
Cohort Characteristics
We have collected clinical data from 30 patients with biallelic
EYS variants from 25 families with a median follow-up of 7
years (range, 0–24 years) (Table 1). Twenty-seven patients
were diagnosed with RP, two siblings had macular dystrophy,
and one isolated patient was diagnosed with CRD. Our
multiethnic cohort consisted of 14 patients from European,
13 from Asian, 2 from African, and 1 from mixed European-
Asian descent. Nine patients had a history of consanguinity.
The current mean age was 45 years (range, 19–75 years), and
sex distribution was equal, with 16 patients (53%) being
male.
Molecular Diagnosis
Of 27 RP patients, 15 carried compound heterozygous variants
(Table 2) and 12 patients had homozygous EYS variants, of
which 8 reported a history of consanguinity. We found 27
different variants: 8 frame shift, 8 nonsense, 8 indels, 3
missense, and 1 splice site variant (Table 3). Seven of these
variants were novel. All missense variants were classified as
pathogenic by SIFT and Polyphen2 algorithms and were
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located in conserved residues of EYS protein. According to the
American College of Medical Genetics (ACMG) classification,
one missense variant, p.(Gly2186Glu), was classified as likely
pathogenic and two variants, p.(Arg2604His) and
p.(Ile2995Asn), were classified as being of uncertain signifi-
cance (Table 3).
In patient XXV, diagnosed with CRD, a homozygous EYS
variant, p.(Tyr3135*) was detected using whole-exome se-
quencing. Besides this change, no other pathogenic variants
were found. The p.(Tyr3135*) variant was previously identified
homozygously in two Dutch siblings, namely, one with CRD
and one with RP,4 and three Spanish siblings with RP.6 In our
cohort, two RP patients were heterozygous carriers of this
variant.
For patient XXIV-1, diagnosed with macular dystrophy,
ABCA4 was initially screened with Sanger sequencing, but no
variants were found. Subsequently, targeted whole-exome
sequencing identified two variants in EYS, c.1299þ5_1299þ8del
and p.(Gly2017Val).23 Using Sanger sequencing, we detected
these EYS variants in his brother, patient XXIV-2. Segregation
analysis of the offspring of patient XXIV-1 confirmed that both
variants were located on different alleles. The first variant
(c.1299þ5_1299þ8del) was novel, whereas the second variant
p.(Gly2017Val) was previously found homozygously in an RP
patient.6 This missense variant was predicted to be pathogenic
by in silico prediction tools (Table 3).
Minigene Splice Assay in HEK293T Cells
To investigate potential splice defects associated with the
novel c.1299þ5_c.1299þ8del variant, wild-type and mutant
minigenes harboring this change were generated and trans-
fected into HEK293T cells. RT-PCR analysis showed that
transfection of the mutant minigene resulted in skipping of
EYS exon 8, whereas transfection of the wild-type minigene
resulted in normal splicing (Fig. 1B). Skipping of EYS exon 8
for the mutant minigene was validated by Sanger sequencing
(Fig. 1C).
Phenotype and Visual Function of Patients With
EYS-Associated RP
Most RP patients developed symptoms of night blindness and
VF constriction in the second and third decade of life, and the
mean age at diagnosis was 30 years (range, 11–56 years).
Demographic information and clinical features are available in
FIGURE 1. In vitro splice assay showing that the c.1299þ5_1299þ8del variant results in the skipping of EYS exon 8. (A) Schematic overview of the
genomic region of EYS exon 7 to 9 including the mutation observed in patient XXIV-1 and wild-type and mutant minigenes that were generated. (B)
RT-PCR analysis of rhodopsin exon 3 (RHO3) to rhodopsin exon 5 (RHO5), actin (loading control), and rhodopsin exon 5 (transfection control) 48
hours after transfection. The wild-type minigene shows a fragment of ~390 bp, which corresponds to normal splicing (RHO3-EYS8-RHO5). The
mutant minigene shows a fragment of ~280 bp, which corresponds to RHO3 and RHO5 spliced together without EYS exon 8. The mutant minigene
showed complete exon skipping of EYS exon 8. (C) Skipping of EYS exon 8 (EYS 8) in cells transfected with the mutant minigene was validated by
Sanger sequencing.
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Table 1. All RP patients had one or more characteristic fundus
feature, such as peripheral retinal degeneration, bone spicule
pigmentations, attenuated retinal vasculature, or pale waxy
optic disc (Supplementary Fig. S2). Refractive error ranged
between þ2 diopter (D) and 13.5 D, with mean spherical
equivalent of 2.75 D. Most patients were mild myopic and
three were high myopes (higher than 6 D).
We gathered 146 visual acuity measurements, with a
mean of 6 measurements per patient (range, 1–22 measure-
ments). Four patients became visually impaired (BCVA worse
than 0.3 logMAR) during follow-up at ages 41, 43, 64, and 70
years and already had constricted VFs (<208) at earlier
examinations. Mixed effects linear regression modeling
showed an overall increase in logMAR visual acuity of
0.015 6 0.002 in the best performing eye per year, which
corresponds to a loss of 0.75 Early Treatment Diabetic
Retinopathy Study (ETDRS) letters per year (P < 0.001) (Fig.
2A).
Fifty-seven Goldmann VF examinations were available,
ranging from one to eight measurements per patient. At first
examination, 11 patients were visually impaired (central VF
radius of the V4e target, <208) and 5 were blind (central VF
radius, <108). One patient became visually impaired during
follow-up at age 39. Ten patients had a central VF larger than
208 at last examination. They did not significantly differ from
patients that were visually impaired in terms of age of onset (P
¼ 0.2262), age at diagnosis (P ¼ 0.259), or age at last
examination (P ¼ 0.136). All 10 patients carried 2 truncating
EYS variants, of which 9 were located in the N-terminal part of
the protein, and 11 in the C-terminal part. Forty-five VFs from
16 patients, were eligible for longitudinal analysis, and the rate
of VF loss of the V4e isopter area was 0.84 6 0.44 ln(deg2)
per year (P < 0.001) (Fig. 2B).
In 23 patients, ffERG was performed: in 15 patients (mean
age, 40 years) no scotopic or photopic responses could be
elicited, in 5 patients (mean age, 43 years) both scotopic and
photopic responses were severely reduced, and in 3 patients
(mean age, 29 years) there were no scotopic responses and
severely reduced photopic responses.
OCT scans of 24 patients and autofluorescence imaging
of 23 patients were available for analysis. In 19 patients, the
ellipsoid layer length was shortened but continuous in the
foveal area, 16 of them had a hyperautofluorescent ring (Fig.
3B), and 3 had a crescent shape hyperautofluorescence
pattern (I, VI-1, and VII-2) (Fig. 3F). In a single patient (VII-
1), the ellipsoid layer was continuous over the width of the
4-mm single line scan, accompanied by a crescent shape
pattern on autofluorescence imaging. The horizontal ellip-
soid zone width in the foveal scan ranged between 0.43 and
5.22 mm (median width, 2.14 mm; n ¼ 62) (Fig. 2D). The
area of the hyperautofluorescent ring ranged between 0.96
and 13.36 mm2 (median area, 4.69 mm2; n ¼ 24). The
ellipsoid zone width was significantly correlated with the
area of the hyperautofluorescent ring, with rs ¼ 0.78 and P
< 0.001 (Fig. 2C). The rate of decline in ellipsoid zone
width was0.057 6 0.017 mm per year (P < 0.01) (n¼ 14).
When calculating the rate of decline as a percentage of
baseline, the rate was3.69% 6 0.51% per year (P < 0.001).
In patients with a distinguishable hyperautofluorescent ring,
the length of the ellipsoid zone was shorter than in patients
with a ‘‘crescent’’ autofluorescence pattern, as described by
Sengillo et al.24 (Fig. 3). Four patients (II-2, XV, XVI, and XX)
had foveal abnormalities in at least one eye (Fig. 3I, 3J), and
it became impossible to discriminate between the different
outer retinal layers because retinal architecture in the
macula, including the fovea, appeared severely distorted.
The majority of RP patients had epiretinal membranes, but
there were no patients with macular holes or tractionalT
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macular edema. Four patients developed cystoid maculop-
athy during follow-up, one patient was treated with
acetazolamide tablets, and two with somatostatin analogue
injections.
Phenotype and Visual Function of a Patient With
EYS-Associated CRD
One isolated patient (XXV) noted both a decrease in visual
acuity and night blindness as first symptoms, and he
previously underwent refractive surgery to correct for high
myopia. At first examination, visual acuity was 0.3 logMAR
in the best eye. Goldmann VF revealed a central relative
scotoma with moderate peripheral constriction (Fig. 4D).
On fundoscopy, the optic disks appeared pale, vessels were
thin, the macular area displayed thinning of the RPE with a
tiny preserved foveal island surrounded by patchy atrophy,
and there were subtle RPE changes in the periphery (Fig.
4A). OCT imaging showed atrophy of the outer retinal layers
in the posterior pole (Fig. 4B), and fundus autofluorescence
showed a hyperautofluorescent ring around the macula and
optic nerve, with hypoautofluorescence inside the ring.
(Fig. 4C).
Phenotype and Visual Function of Patients with
EYS-Associated Macular Dystrophy
The proband (XXIV-2) was the youngest in a family of five
siblings; he suffered from decreased visual acuity from the age
of 7. He was first examined at age 12, and his binocular visual
acuity was 1.0 logMAR with eccentric fixation. At age 22, he
was diagnosed with juvenile macular dystrophy, visual acuity
was 0.8 logMAR, and funduscopy revealed a bull’s eye
maculopathy. Central VF testing with Humphrey Field Analyzer
10-2 showed a central scotoma, and color vision testing with
Lanthony’s desaturated 15-Hue test revealed a tritan defect.
ffERG showed normal scotopic and photopic responses. At age
23, pronounced macular atrophy was seen on OCT imaging
(Fig. 5G). His older brother (XXIV-1) noted a decrease in visual
acuity and color vision problems from the age of 18. At age 32,
visual acuity was 0.3 logMAR and funduscopy revealed normal
foveal reflexes, perimacular RPE alterations, and few tiny white
dots, with normal aspect of the peripheral retina. OCT imaging
showed atrophy of the ellipsoid zone in the fovea, and fundus
autofluorescence revealed a hyperautofluorescent ring (Figs.
5A–C). At age 36, ffERG rod and cone responses were within
normal range, and multifocal electroretinogram showed
FIGURE 2. Scatterplots show (A) visual acuity versus age, (B) visual field area of the V4e isopter versus age, (D) ellipsoid zone width versus age, and
(C) ellipsoid zone width versus hyperautofluorescent ring area.
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decreased foveal responses (Supplementary Fig. S3). At age 38,
visual acuity was 0.7 logMAR and OCT imaging showed
atrophy of all outer retinal layers and thinning of the RPE.
Fundus autofluorescence revealed a larger hyperautofluores-
cent ring surrounding the hypoautofluorescent macula (Figs.
5D and 5F).
DISCUSSION
In this study, we have assessed the spectrum of retinal disease
and the course of visual function in 30 patients carrying
biallelic EYS variants. Twenty-seven patients had RP, one
patient had CRD, and two patients had macular dystrophy,
based on clinical characteristics, functional testing, and retinal
imaging. EYS mutations are one of the most common causes of
autosomal recessive retinitis pigmentosa in Asia and Europe.
Novel findings included the presence of homozygous EYS
mutations in CRD patients and compound heterozygous EYS
mutations in patients with macular dystrophy.
The age of onset in RP patients ranged from 7 to 51 years,
and all had one or more typical fundus features corresponding
with RP (Supplementary Fig. S1). Four patients became visually
impaired (BCVA worse than 0.3 logMAR) during follow-up at
ages 41, 43, 64, and 70 years. Mixed effects linear regression
FIGURE 3. Optical coherence tomography, fundus autofluorescence, fundus photography, and visual field of three RP patients with different RP
phenotypes. Patients II-3 (age 23) shows a typical RP phenotype with (A) shortening of the ellipsoid layer length and (B) a hyperautofluorescent
ring surrounding the fovea, (C) the optic disk appears pale and vessels are narrow. Visual field (D) is severely constricted (~108). Patient VII-2 (age
41) has a milder phenotype, (E) the ellipsoid layer length is longer, and there is (F) a ‘‘crescent-shaped’’ hyperautofluorescent pattern visible. (G)
The optic disk appears pink and vessels are narrow. There is decreased sensitivity of the peripheral visual field (H), with an absolute scotoma
nasally. Patient XX (age 73) has end-stage RP, and (I) the ellipsoid zone and other outer segment layers are no longer discernible. There is a (J) small
relatively hyperautofluorescent patch in the perifoveal area, surrounded by hypoautofluorescence, and the fovea itself appears hypoautofluorescent
as well. In fundo (K), the optic disk appears pale, vessels are very narrow, and there is extensive atrophy of the RPE and choriocapillaris with bone
spicule pigmentations. A small island of RPE remains in the macula with RPE-alterations. The visual field (L) is severely constricted (<108).
FIGURE 4. Autofluorescence, SD-OCT, and fundus pictures of patient with CRD. (A) Fundus autofluorescence of patient XXV shows a
hyperautofluorescent ring within the vascular arcade, surrounding the macular area, which appears patchy, with diffuse hypoautofluorescent
lesions. The fovea appears hypoautofluorescent. (B) On OCT, there is a foveal empty space, the outer retinal layers are distorted, and the ellipsoid
zone can no longer be distinguished. (C) Atrophy of the posterior pole with discernable choroidal vasculature, and the retinal vessels are attenuated.
(D) Goldmann visual field reveals a relative central scotoma with mild to moderate peripheral constriction.
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modeling showed an overall increase in logMAR visual acuity of
0.015 in the best performing eye per year, which corresponds
to a loss of 0.75 ETDRS letters per year (P < 0.001). One study
in a heterogeneous group of RP patients found a decline in
visual acuity of 2.3 ETDRS letters per year. This would place
EYS-associated RP in the milder spectrum of disease.25 Based
on VF constriction, 11 out of 27 RP patients were visually
impaired (41%) and 5 were blind (19%) according to World
Health Organization criteria at first examination in our centers.
The rate of peripheral VF loss for the V4e target was0.84 6
0.44 ln(deg2) per year in our cohort. McGuigan et al.21
reported the rate as23% of normal per year. Ten RP patients
had a central VF larger than 208 at last follow-up (mean age, 39
years). They did not differ from RP patients with VF
constriction in age of onset or age at last examination. All 10
of these patients carried compound heterozygous or homozy-
gous truncating variants.
Differences in disease manifestation and progression are
often attributed to a difference in underlying causal variants
(e.g. missense versus truncating variants). Three out of 27 RP
patients carried 1 heterozygous missense EYS variant, and 1
truncating EYS variant. There were no patients with homozy-
gous missense EYS variants; therefore, we could not study
whether missense variants were associated with milder retinal
disease in our cohort. Siblings with the same EYS genotype can
differ substantially in age of onset, disease presentation, and
rate of disease progression. Our study was not suited to
determine genotype-phenotype correlations in detail, as many
variants were observed only once.
The estimated decline in ellipsoid zone width was57 6 17
lm per year, which was less than in previous publications
where yearly decline varied between 76.4 lm to 248
lm.25–29 However, these estimates were based on RP patients
with different underlying genetic defects and inheritance
modes. We also calculated the rate of shortening as a
FIGURE 5. Infrared imaging, OCT imaging, and fundus photography in patients with macular dystrophy. Disease progression of EYS-associated
macular dystrophy in patient XXIV-1 by using SD-OCT scans, FAF, and fundus images of the right eye. (A–C) At age 32, SD-OCT scan shows foveal
atrophy with local disruption of the ellipsoid zone and thinning of the outer nuclear layer, and on FAF a hyperautofluorescent ring is discernable
surrounding the fovea. Fundus photograph reveals a normal optic disk, normal caliber of the retinal vessels, and subtle RPE alterations in the foveal
region but no abnormalities in the peripheral retina. (D–F) At age 38, SD-OCT shows progression of the foveal atrophy with disruption of the inner
retinal layers, hyperreflective deposits, and thinning of the RPE. FAF shows a more advanced bull’s-eye maculopathy with a hypo-autoflorescent
fovea and a hyperreflective ring. Fundus photograph reveals a hypopigmented fovea surrounded by RPE alterations and RPE atrophy, and there were
no peripheral abnormalities. (G) SD-OCT of patient XXIV-2 at age 23, showing macular atrophy.
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percentage from baseline to enable comparison with two
studies in EYS patients. Our estimate was 3.69% 6 0.51%,
which corresponds with the findings of two previous studies,
reporting a rate of 4.65% 6 2.89% (n ¼ 12)22 and 5.6% 6
2.6% per year (n ¼ 4).21
Two-thirds of RP patients in our cohort had typical
hyperautofluorescent rings, and one-third had a crescent shape
hyperautofluorescent pattern, as described by Sengillo et al.24
The crescent pattern was associated with larger VFs and,
therefore, milder disease progression. Three out of four
patients had two mutations near the C-terminal domain, which
could have a less detrimental impact on protein structure or
function. Additional studies would be most helpful to study the
effect of these mutations on the different isoforms.
Three cases of EYS-associated CRD have been published so
far; the first case was a Dutch patient that carried the same
homozygous variant as our CRD patient, p.(Tyr3135*).4 The
second case was a Japanese patient, carrying compound
heterozygous EYS variants, p.(Tyr2935*) and p.(Ser1653fs).
Segregation analysis confirmed that these variants were located
on different alleles. Each separate variant homozygous, as well
as the identical compound heterozygous combination of these
variants, were previously identified as causal in RP pa-
tients.9,30–32 The third case was a French patient with
compound heterozygous variants, p.(Trp558*) and p.(Asn745-
Ser). The pathogenicity of the missense variant was question-
able, as it proved to be not conserved, and the pathogenicity is
uncertain according to the ACMG classification.18 The homo-
zygous nonsense variant p.(Tyr3135*) that our CRD patient as
well as the first mentioned CRD case carried was also detected
in RP patients,4,5 including in two RP patients of this cohort.
The variant is located in the last EYS exon and leads to a
premature stop codon. Functional assays might reveal whether
the variant leads to nonsense-mediated decay or the formation
of a C-terminal-truncated EYS protein. It is unclear why
identical genotypes can result in both RP and CRD phenotypes.
The EYS variants found in CRD patients did not cluster in a
specific domain. Of the four known EYS isoforms, only the two
long isoforms (isoform 1 and 4) are predicted to be affected by
the mutations, as all CRD-associated variants are all located
after the 594th amino acid. Unfortunately, this does not help
explain the difference in phenotype because some of the
underlying genotypes were also found in RP patients. The
presence of genetic and epigenetic modifiers, or environmen-
tal factors, could also play a role in the observed differences in
phenotype in these patients.
Macular dystrophy is an IRD in which the central retina is
primarily affected and peripheral photoreceptor function is
spared. Patients XXIV-1 and XXIV-2 presented with an isolated
macular dystrophy, with a normal ffERG. Targeted whole-
exome sequencing identified compound heterozygous EYS
variants: c.1299þ5_1299þ8del and c.6050G>T. To assure the
functional effect of the splice site variant, we generated a
mutant minigene. RT-PCR analysis showed that transfection of
the mutant minigene resulted in skipping of EYS exon 8,
suggesting that similar missplicing events can occur in the
retina. This variant has not been described in other IRD
patients; therefore, it is not clear whether this variant is solely
associated with macular dystrophy or can also lead to other
phenotypes. Exon 8 codes for the fifth EGF-like domain that is
part of all four known EYS isoforms. EGF-like domains are
usually located in the extracellular domain of membrane-bound
proteins, such as EYS, and are important for the structural
integrity of the protein. The second variant, c.6050G>T, was
previously found homozygous in an RP patient.6 EYS is
expressed in the outer segments of both rods and cones and
is thought to be crucial for the stability of the ciliary axonema
and photoreceptor homeostasis in humans. In several mammal
lineages, such as rodents, EYS is not expressed, which limits
the availability of animal models that better mimic human
anatomy and physiology. EYS zebrafish knockout studies
showed CRD pattern of retinal degeneration,16 and RP or
macular dystrophy phenotypes have not been described in
animals that are mutant for Eys.
Because molecular testing can uncover pathogenic variants
in genes that have not been associated with the phenotype of
interest, it remains crucial to perform segregation analysis and
to keep looking for variants in other genes. Reassessing the
phenotype might be worthwhile, especially in patients with
end-stage disease in whom discriminating between different
subtypes of IRD might prove difficult, as both central and
peripheral retinal architecture are frequently severely distort-
ed. To better understand the pathophysiology of EYS-associat-
ed IRDs, it is essential to perform functional studies that focus
on the effect of mutations on the different EYS isoforms and
their effect within the retina.
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